AU2016290963B2 - Pyrrolidine carboxamido derivatives and methods for preparing and using the same - Google Patents
Pyrrolidine carboxamido derivatives and methods for preparing and using the same Download PDFInfo
- Publication number
- AU2016290963B2 AU2016290963B2 AU2016290963A AU2016290963A AU2016290963B2 AU 2016290963 B2 AU2016290963 B2 AU 2016290963B2 AU 2016290963 A AU2016290963 A AU 2016290963A AU 2016290963 A AU2016290963 A AU 2016290963A AU 2016290963 B2 AU2016290963 B2 AU 2016290963B2
- Authority
- AU
- Australia
- Prior art keywords
- compound
- disease
- composition
- pct
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- QELVTJGJFUNNNN-GSDHBNRESA-N CCCCCCCCCC(N(CCC1)[C@@H]1C(N(CCC1)[C@@H]1C(NCC(N[C@@H](Cc(cc1)ccc1O)C(O)=O)=O)=O)=O)=O Chemical compound CCCCCCCCCC(N(CCC1)[C@@H]1C(N(CCC1)[C@@H]1C(NCC(N[C@@H](Cc(cc1)ccc1O)C(O)=O)=O)=O)=O)=O QELVTJGJFUNNNN-GSDHBNRESA-N 0.000 description 2
- CSNSXRDPSUDGOD-HHIOAARCSA-N CCCCCCCCCC(N[C@@H](C(C)C)C(N(CCC1)[C@@H]1C(N(CCC1)[C@@H]1C(NCC(N[C@@H](Cc(cc1)ccc1O)C(O)=O)=O)=O)=O)=O)=O Chemical compound CCCCCCCCCC(N[C@@H](C(C)C)C(N(CCC1)[C@@H]1C(N(CCC1)[C@@H]1C(NCC(N[C@@H](Cc(cc1)ccc1O)C(O)=O)=O)=O)=O)=O)=O CSNSXRDPSUDGOD-HHIOAARCSA-N 0.000 description 2
- MEPBNSKLKFXDMJ-RNHIQORTSA-N CCCCCCCCCCCCCCCC(N[C@@H](C(C)C)C(N(CCC1)[C@@H]1C(N(CCC1)[C@@H]1C(NCC(N[C@@H](Cc(cc1)ccc1O)C(O)=O)=O)=O)=O)=O)=O Chemical compound CCCCCCCCCCCCCCCC(N[C@@H](C(C)C)C(N(CCC1)[C@@H]1C(N(CCC1)[C@@H]1C(NCC(N[C@@H](Cc(cc1)ccc1O)C(O)=O)=O)=O)=O)=O)=O MEPBNSKLKFXDMJ-RNHIQORTSA-N 0.000 description 2
- 0 *N(CCC1)[C@@]1C(N)=O Chemical compound *N(CCC1)[C@@]1C(N)=O 0.000 description 1
- JPUDJRLHUMPJQU-LTQCFNPWSA-N CCCCC/C=C\C/C=C\CCCCCCCC(N(CCC1)[C@@H]1C(N(CCC1)[C@@H]1C(NCC(N[C@@H](Cc(cc1)ccc1O)C(O)=O)=O)=O)=O)=O Chemical compound CCCCC/C=C\C/C=C\CCCCCCCC(N(CCC1)[C@@H]1C(N(CCC1)[C@@H]1C(NCC(N[C@@H](Cc(cc1)ccc1O)C(O)=O)=O)=O)=O)=O JPUDJRLHUMPJQU-LTQCFNPWSA-N 0.000 description 1
- MCBISDJDXKKWLW-VMPREFPWSA-N CCCCCCCCCCCCCCCC(NCC(N(CCC1)[C@@H]1C(NCC(N[C@@H](Cc(cc1)ccc1O)C(O)=O)=O)=O)=O)=O Chemical compound CCCCCCCCCCCCCCCC(NCC(N(CCC1)[C@@H]1C(NCC(N[C@@H](Cc(cc1)ccc1O)C(O)=O)=O)=O)=O)=O MCBISDJDXKKWLW-VMPREFPWSA-N 0.000 description 1
- NBIVAORDRGHHCE-KVBYWJEESA-N CCCCCCCCCCCCCCCC(N[C@@H](Cc1ccccc1)C(N(CCC1)[C@@H]1C(NCC(N[C@@H](Cc(cc1)ccc1O)C(O)=O)=O)=O)=O)=O Chemical compound CCCCCCCCCCCCCCCC(N[C@@H](Cc1ccccc1)C(N(CCC1)[C@@H]1C(NCC(N[C@@H](Cc(cc1)ccc1O)C(O)=O)=O)=O)=O)=O NBIVAORDRGHHCE-KVBYWJEESA-N 0.000 description 1
- VAUNUZLXIMPAGX-NSHDSACASA-N OC([C@H](CC(CC=C1)=CC=C1O)NCC=O)=O Chemical compound OC([C@H](CC(CC=C1)=CC=C1O)NCC=O)=O VAUNUZLXIMPAGX-NSHDSACASA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
- C07K5/0823—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp and Pro-amino acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrrole Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150097040 | 2015-07-08 | ||
| KR20150097040 | 2015-07-08 | ||
| PCT/US2016/041563 WO2017008033A1 (en) | 2015-07-08 | 2016-07-08 | Pyrrolidine carboxamido derivatives and methods for preparing and using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2016290963A1 AU2016290963A1 (en) | 2017-09-28 |
| AU2016290963B2 true AU2016290963B2 (en) | 2019-06-27 |
Family
ID=57686085
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016290963A Active AU2016290963B2 (en) | 2015-07-08 | 2016-07-08 | Pyrrolidine carboxamido derivatives and methods for preparing and using the same |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US20170008924A1 (https=) |
| EP (1) | EP3265443B1 (https=) |
| JP (1) | JP6692371B2 (https=) |
| KR (1) | KR101963559B1 (https=) |
| CN (2) | CN115368438A (https=) |
| AU (1) | AU2016290963B2 (https=) |
| BR (1) | BR112017022857B1 (https=) |
| CA (1) | CA2980001C (https=) |
| CL (1) | CL2017002689A1 (https=) |
| CO (1) | CO2017010530A2 (https=) |
| DK (1) | DK3265443T3 (https=) |
| EA (1) | EA033342B1 (https=) |
| ES (1) | ES2784703T3 (https=) |
| IL (1) | IL254327B (https=) |
| MX (1) | MX2017013335A (https=) |
| MY (1) | MY189670A (https=) |
| NZ (1) | NZ735250A (https=) |
| PH (1) | PH12017501790A1 (https=) |
| PL (1) | PL3265443T3 (https=) |
| PT (1) | PT3265443T (https=) |
| SA (1) | SA517390034B1 (https=) |
| SG (1) | SG11201707145QA (https=) |
| UA (1) | UA121890C2 (https=) |
| WO (1) | WO2017008033A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ735250A (en) | 2015-07-08 | 2020-08-28 | Research & Business Found Sungkyunkwan Univ | Pyrrolidine carboxamido derivatives and methods for preparing and using the same |
| EP3759070A4 (en) * | 2018-02-28 | 2021-12-08 | Bridge Biotherapeutics, Inc. | WATER-SOLUBLE SALTS OF LIPID PEPTIDES AND THEIR PREPARATION AND USE PROCESSES |
| SG11202104802RA (en) | 2018-11-08 | 2021-06-29 | Arizona Board Of Regents On Behalf Arizona State Univ | Synthetic immunomodulation with a crispr super-repressor in vivo |
| KR102104507B1 (ko) | 2019-08-23 | 2020-04-24 | 브릿지바이오테라퓨틱스(주) | 팔미토일-l-프롤릴-l-프롤릴-글리실-l-타이로신 나트륨을 포함하는 약제학적 제제 및 이의 제조방법 |
| CN114585383B (zh) * | 2019-10-17 | 2024-04-19 | 艾弼生物科技有限公司 | 包含rip激酶抑制剂的用于防脱发或促生发的组合物 |
| KR102268702B1 (ko) * | 2019-10-17 | 2021-06-24 | 주식회사 에피바이오텍 | Rip 키나아제 억제제를 포함하는 탈모 방지 또는 발모 촉진용 조성물 |
| KR102394875B1 (ko) * | 2021-05-11 | 2022-05-06 | 주식회사 비드테크 | 피롤리딘을 링커로 포함하는 화합물 및 이를 포함하는 약학 조성물 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010059922A1 (en) * | 2008-11-21 | 2010-05-27 | Ligand Pharmaceuticals Incorporated | Pyrrolidine carboxamide compounds |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3839127A1 (de) * | 1988-11-19 | 1990-05-23 | Hoechst Ag | Pyrrolidon-2-carbonsaeure-derivate mit psychotroper wirkung |
| AUPM906594A0 (en) | 1994-10-26 | 1994-11-17 | Peptide Technology Limited | Synthetic polyunsaturated fatty acid analogues |
| ES2243996T3 (es) * | 1996-05-01 | 2005-12-01 | Ortho-Mcneil Pharmaceutical, Inc. | Derivados carboxamida de pirrolidina, piperidina y hexahidroazepina utilizados en el tratamiento de trastornos de trombosis. |
| EP1004578B1 (en) * | 1998-11-05 | 2004-02-25 | Pfizer Products Inc. | 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives |
| US7049283B2 (en) * | 2000-12-06 | 2006-05-23 | Novartis Ag | Pharmaceutical compositions for the oral delivery of pharmacologically active agents |
| JP2002297664A (ja) | 2001-04-03 | 2002-10-11 | Fuji Photo Film Co Ltd | 画像データ提供装置および画像データ提供プログラム |
| WO2003007876A2 (en) | 2001-06-25 | 2003-01-30 | University Of Massachusetts | N-fatty acid-amino acid conjugates and therapeutic uses |
| DE10259672A1 (de) * | 2002-12-18 | 2004-07-01 | Basf Ag | Verfahren zur Herstellung von Alkoxycarbonylamino-triazinen |
| JP2006157623A (ja) * | 2004-11-30 | 2006-06-15 | Funai Electric Co Ltd | 放送受信装置 |
| WO2006113942A2 (en) * | 2005-04-20 | 2006-10-26 | Schering Corporation | Method of inhibiting cathepsin activity |
| US7842662B2 (en) * | 2006-11-10 | 2010-11-30 | Cara Therapeutics, Inc. | Synthetic peptide amide dimers |
| JP2010536341A (ja) * | 2007-08-15 | 2010-12-02 | アムニクス， インコーポレイテッド | 生物学的に活性なポリペプチドの特性を改変するための組成物および方法 |
| CN102067197A (zh) | 2008-06-26 | 2011-05-18 | 夏普株式会社 | 显示装置和电子设备 |
| JP5740689B2 (ja) | 2008-08-18 | 2015-06-24 | エンテラ バイオ エルティーディー． | タンパク質の経口投与用の方法および組成物 |
| KR101033041B1 (ko) | 2008-11-13 | 2011-05-09 | 조선대학교산학협력단 | 경보장치 고정 장치 |
| KR101151878B1 (ko) | 2010-06-08 | 2012-05-31 | 미원상사주식회사 | 지방산 트리펩타이드염 및 이를 함유하는 항균 조성물 |
| KR20100110282A (ko) | 2010-08-16 | 2010-10-12 | 황규태 | 쓰레기봉투용 뚜껑 |
| KR101348284B1 (ko) * | 2010-09-09 | 2014-01-03 | 주식회사 나이벡 | 인간 유래 세포 투과성 펩타이드와 생리활성 펩타이드 결합체 및 그 용도 |
| KR20120048864A (ko) | 2010-11-08 | 2012-05-16 | 주식회사 네오디엠 | 트리 펩타이드 유도체를 함유한 아토피 피부염 예방 및 치료용 조성물과 그 제조방법 |
| KR20130038426A (ko) | 2011-10-07 | 2013-04-18 | 성균관대학교산학협력단 | 지방산이 결합된 항당뇨 펩티드가 소수성 결합된 글리콜 키토산 히드로겔 및 이를 포함하는 당뇨병 예방 또는 치료용 약학적 조성물 |
| KR101359886B1 (ko) | 2011-12-28 | 2014-02-12 | 성균관대학교산학협력단 | 스매드 6번(Ｓｍａｄ６)으로부터 유래된 펩타이드를 유효성분으로 포함하는 패혈증 또는 패혈성 쇼크의 치료용 조성물 |
| US20150368197A1 (en) * | 2012-06-21 | 2015-12-24 | Radikal Therapeutics Ins. | Compositions and methods for treatment of inflammatory diseases of the lung |
| WO2015057820A2 (en) * | 2013-10-15 | 2015-04-23 | Roberts S Kenny | Peptide constructs and well-defined aggregates thereof |
| NZ735250A (en) | 2015-07-08 | 2020-08-28 | Research & Business Found Sungkyunkwan Univ | Pyrrolidine carboxamido derivatives and methods for preparing and using the same |
-
2016
- 2016-07-08 NZ NZ735250A patent/NZ735250A/en unknown
- 2016-07-08 MY MYPI2017703626A patent/MY189670A/en unknown
- 2016-07-08 AU AU2016290963A patent/AU2016290963B2/en active Active
- 2016-07-08 BR BR112017022857-2A patent/BR112017022857B1/pt active IP Right Grant
- 2016-07-08 PT PT168220531T patent/PT3265443T/pt unknown
- 2016-07-08 PL PL16822053T patent/PL3265443T3/pl unknown
- 2016-07-08 US US15/205,853 patent/US20170008924A1/en not_active Abandoned
- 2016-07-08 CN CN202210589872.0A patent/CN115368438A/zh active Pending
- 2016-07-08 DK DK16822053.1T patent/DK3265443T3/da active
- 2016-07-08 ES ES16822053T patent/ES2784703T3/es active Active
- 2016-07-08 EP EP16822053.1A patent/EP3265443B1/en active Active
- 2016-07-08 EA EA201791945A patent/EA033342B1/ru not_active IP Right Cessation
- 2016-07-08 MX MX2017013335A patent/MX2017013335A/es active IP Right Grant
- 2016-07-08 JP JP2017551335A patent/JP6692371B2/ja active Active
- 2016-07-08 CA CA2980001A patent/CA2980001C/en active Active
- 2016-07-08 WO PCT/US2016/041563 patent/WO2017008033A1/en not_active Ceased
- 2016-07-08 SG SG11201707145QA patent/SG11201707145QA/en unknown
- 2016-07-08 UA UAA201710114A patent/UA121890C2/uk unknown
- 2016-07-08 KR KR1020177028207A patent/KR101963559B1/ko active Active
- 2016-07-08 CN CN201680020220.8A patent/CN107531753A/zh active Pending
-
2017
- 2017-09-04 IL IL254327A patent/IL254327B/en active IP Right Grant
- 2017-09-27 SA SA517390034A patent/SA517390034B1/ar unknown
- 2017-09-28 PH PH12017501790A patent/PH12017501790A1/en unknown
- 2017-10-13 CO CONC2017/0010530A patent/CO2017010530A2/es unknown
- 2017-10-23 CL CL2017002689A patent/CL2017002689A1/es unknown
-
2018
- 2018-03-14 US US15/921,596 patent/US11365215B2/en active Active
-
2022
- 2022-08-03 US US17/817,252 patent/US20230018246A1/en not_active Abandoned
-
2024
- 2024-04-26 US US18/648,015 patent/US20240352067A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010059922A1 (en) * | 2008-11-21 | 2010-05-27 | Ligand Pharmaceuticals Incorporated | Pyrrolidine carboxamide compounds |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240352067A1 (en) | Pyrrolidine carboxamido derivatives and methods for preparing and using the same | |
| CN102781436B (zh) | 纤维肌痛综合征的治疗方法 | |
| JP6180420B2 (ja) | 増殖性疾患の治療のためのｈｓｐ９０阻害剤と組み合わせた２−カルボキサミドシクロアミノウレア誘導体 | |
| US20150238486A1 (en) | Novel uses | |
| KR20190077131A (ko) | 선택적 s1p1 수용체 아고니스트를 포함하는 약학 조합물 | |
| JP2026048875A (ja) | インスリン耐性における使用方法のための治療化合物 | |
| CA2788150C (en) | Compounds for suppressing a peripheral nerve disorder induced by an anti-cancer agent | |
| EP3801546B1 (en) | Indole compound for treating interstitial cystitis | |
| US20240287042A1 (en) | Novel compound having inhibitory activity against pendrin, and pharmaceutical uses thereof | |
| JP7759109B2 (ja) | Ｅｏｍｅｓ陽性ＣＤ４陽性Ｔ細胞の増加に起因する進行型疾患治療剤 | |
| HK1243078B (en) | Pyrrolidine carboxamido derivatives and methods for preparing and using the same | |
| JPWO2017217071A1 (ja) | セレノプロテインｐ活性阻害作用を有する成分を含有する、肺高血圧症の予防又は治療剤 | |
| JP7821740B2 (ja) | 代謝異常を治療するためのベンズイミダゾール化合物 | |
| KR20130036493A (ko) | 신규한 케르세틴 유도체, 3',4'-디플루오로케르세틴, 그 제조방법 및 그 용도 | |
| US20220024976A1 (en) | Salt and crystalline forms of rapastinel | |
| WO2017082393A1 (ja) | 緑内障予防治療剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HB | Alteration of name in register |
Owner name: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY Free format text: FORMER NAME(S): REASEARCH & BUSINESS FOUNDATION SUNGKYUNKWAN UNIVERSITY ; KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY Owner name: RESEARCH & BUSINESS FOUNDATION SUNGKYUNKWAN UNIVER Free format text: FORMER NAME(S): REASEARCH & BUSINESS FOUNDATION SUNGKYUNKWAN UNIVERSITY ; KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY |
|
| FGA | Letters patent sealed or granted (standard patent) |